BioLife Solutions (BLFS) develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.
Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryo-protectants.
In addition, the company provides custom product formulation and packaging services; contract aseptic manufacturing formulation, fill, and finish services of liquid media products; and precision thermal packaging products and cloud-hosted Web applications.
It markets its products to the regenerative medicine, bio-banking, drug discovery markets, comprising hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets.
BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
July 3, 2025
RegMed Investors (RMi) Closing Bell: Feeling the high, just haven’t exhaled yet
June 27, 2025
RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower
June 26, 2025
RegMed Investors (RMi) Closing Bell: Econs cried havoc and let slip the algo dogs of electronic trading
June 25, 2025
RegMed Investors (RMi) Closing Bell: Electronic trading slipped in to minimize earlier share pricing blast circumference
June 24, 2025
RegMed Investors (RMi) Closing Bell: clicking on the after burners
June 23, 2025
RegMed Investors (RMi) Closing Bell: Sector has minor collateral damage
June 20, 2025
RegMed Investors (RMi) Closing Bell: Luckily, the canopy opened
June 18, 2025
RegMed Investors (RMi) Closing Bell: a sector of flash bang pricing movements
June 17, 2025
RegMed Investors (RMi) Closing Bell: I love the smell of gene therapy sentiment in the morning!!
June 16, 2025
RegMed Investors (RMi) Closing Bell: My view/words ring true
35 companies, 1 interpreter!
Insight, foresight and recommendation
BioLife Solutions (BLFS) – Opened 2018 at $5.96, droppen into February at $5.33, seeing a low of $4.73 yet was trading up at $5.33 on 2/16 after the usual response to news. BLFS on 2/13/18 ... BLFS executed an OEM agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under private label to MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors